At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganzel, Chezi, Wang, Xin V., Rowe, Jacob M., Richards, Susan M., Buck, Georgina, Marks, David I., Litzow, Mark R., Paietta, Elisabeth M., Foroni, Letizia, Luger, Selina M., Willman, Cheryl L., Mullighan, Charles G., Roberts, Kathryn G., Wiernik, Peter H., Douer, Dan, Lazarus, Hillard M., Tallman, Martin S., Goldstone, Anthony H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687130/
https://www.ncbi.nlm.nih.gov/pubmed/32220069
http://dx.doi.org/10.1111/bjh.16616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687130/
https://www.ncbi.nlm.nih.gov/pubmed/32220069
http://dx.doi.org/10.1111/bjh.16616

Ejemplares similares